Converge Bio, a provider of generative AI-powered drug discovery solutions for biotech and pharmaceutical companies, raised $5.5 million in seed funding.
TLV Partners led the investment round.
Converge Bio leverages generative artificial intelligence (AI) to accelerate the drug discovery and development process. Their platform utilizes large language models (LLMs) trained on extensive biological and chemical data—including DNA, RNA, protein sequences, and small molecules—to assist biotech and pharmaceutical companies in developing more effective drugs more efficiently.
In the official press announcement, Dov Gertz, co-founder and CEO of Converge BioDov Gertz, co-founder and CEO of Converge Bio, said: Generative AI has emerged as a powerful tool for drug discovery and development, with dozens of AI-discovered drugs currently in clinical trials.”
“Biological languages, like DNA and RNA, aren’t just random sequences — they have intricate structures and rules, similar to the grammar and syntax of spoken languages.” “Just like how ChatGPT can instantly generate a string of words to answer a question, a model trained on biological data can help rapidly design optimized mRNA sequences for vaccines, cutting months or years from the process,” added Dov Gertz.
With the new funds, Converge Bio intends to scale its team of AI scientists to broaden the capabilities of its platform, driving innovation in biotech research and development.